InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
无可用的信号评分。
Discover the complete record of transactions filed by Stenhouse Mark. Officer active across 2 companies, notably Prometheus Biosciences, Inc.. Aggregated, 6 disclosures have been published. History available since 9 December 2022. The latest transaction was disclosed on 3 June 2025 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 条申报中的 6 条
Stenhouse Mark is a declarant linked to Phathom Pharmaceuticals, Inc., where he is Director, and to Prometheus Biosciences, Inc., where he is Chief Operating Officer. His record includes 6 filings, and across the recent filings we hold, the period runs from 2022-12-13 to 2025-06-05, with the modal transaction nature shown as Attribution.